Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2018

Open Access 01-12-2018 | Research

DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway

Authors: Sheng-Bing Liu, Xue-Ping Lin, Ying Xu, Zhong-Fei Shen, Wei-Wei Pan

Published in: Journal of Ovarian Research | Issue 1/2018

Login to get access

Abstract

Background

The death-domain-associated protein (DAXX) was originally identified as a protein that binds to the transmembrane death receptor FAS and enhances both FAS-induced and transforming growth factor-β-dependent apoptosis. In a previous study, we found that nude mice injected with DAXX-overexpressing cells (ES-2-DAXX) accumulated large concentrations of first-generation ascites cells (I ascites cells). The role of DAXX in the development of ascites is unknown. The aim of this study was to analyze the effect of DAXX on proliferation and migration of ascites cells in ovarian cancer in vitro and in vivo.

Methods

Nude mice were housed in cages with a 14:10 h light:dark cycle; water and food were provided ad libitum. ES-2-DAXX cells (1×106) were injected intraperitoneally into athymic nude mice (8-week-old female mice). After 4 weeks, I ascites cells were collected. The I ascites cells were injected intraperitoneally into athymic nude mice (8-week-old female mice). After 4 weeks, II ascites cells were collected and cultured. Ascites cell survival, migration, and colony formation were measured using colony formation and cell growth assays. Immunofluorescent staining revealed the co-localization of DAXX and promyelocytic leukemia protein (PML) in ascites cell nuclei. Western blotting and immunohistochemistry showed that extracellular signal-related kinase (p-ERK) 1/2 and CEBP-β were highly expressed in tumor tissues formed by II ascites cells. Through immunoprecipitation, we also found that DAXX can interact with CEBP-β.

Results

DAXX enhanced ascites cell survival, migration, and colony formation. DAXX and PML nuclear foci dramatically increased in a passage-dependent manner in ascites cells, DAXX promoted the tumor growth of ascites cells in vivo, increased ascites cell proliferation in vivo, and enhanced ascites cell survival and migration by activating the ERK signalling pathway and integrating with CEBP-β.

Conclusions

DAXX can interact with CEBP-β. DAXX can induce ovarian cancer ascites formation by activating the ERK signal pathway and binding to CEBP-β.
Literature
1.
Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19–24.CrossRef
2.
Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28.CrossRef
3.
Lane D, Robert V, Grondin R, Rancourt C, Piché A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer. 2007;121:1227–37.CrossRef
4.
Lane D, Goncharenko-Khaider N, Rancourt C, Piché A. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene. 2010;29:3519–31.CrossRef
5.
Ahmed N, Riley C, Oliva K, Rice G, Quinn M. Ascites induces modulation of 6β1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer. 2005;92:1475–85.CrossRef
6.
Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29:2875–84.PubMed
7.
Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour–host interaction in ovarian cancer. Eur J Cancer. 2011;47:1883–9.CrossRef
8.
Pan WW, Zhou JJ, Liu XM, Xu Y, Guo LJ, Yu C, Shi QH, Fan HY. Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance. J Biol Chem. 2013;288:13620–30.CrossRef
9.
Dolznig H, Rupp C, Puri C, et al. Modeling Colon Adenocarcinomas in Vitro: A 3D Co-Culture System Induces Cancer-Relevant Pathways upon Tumor Cell and Stromal Fibroblast Interaction. Am J Pathol. 2011;179:487–501.CrossRef
10.
Fischbach C, Kong HJ, Hsiong SX, et al. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc Natl Acad Sci U S A. 2009;106:399–404.CrossRef
11.
Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene. 2009;28:461–8.CrossRef
12.
Pan WW, Yi FP, Cao LX, Liu XM, Shen Z, Bu Y, Xu Y, Fan HY, Song FZ. DAXX silencing suppresses mouse ovarian surface epithelial cell growth by inducing senescence and DNA damage. Gene. 2013;526:287–94.CrossRef
13.
Wethkamp N, Klempnauer KH. Daxx is a transcriptional repressor of CCAAT/enhancer-binding protein β. J Biol Chem. 2009;284:28783–94.CrossRef
14.
Innao P, Pothisuwan M, Pengsa P. Does human epididymis protein 4 (HE4) have a role in prediction of recurrent epithelial ovariancancer. Asian Pac J Cancer Prev. 2016;17:4483–6.PubMed
15.
Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203.CrossRef
16.
Auer K, Bachmayr-Heyda A, Sukhbaatar N, Aust S, Schmetterer KG, Meier SM, Gerner C, Grimm C, Horvat R, Pils D. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget. 2016;7:61336–54.CrossRef
17.
Chen LY, Chen JD. DAXX silencing sensitizes cells to multiple apoptotic pathways. Mol Cell Biol. 2003;23:7108–21.CrossRef
18.
Yang X, Khosravi-Far R, Chang HY, Baltimore D. DAXX, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067–76.CrossRef
19.
Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ, Chen JD. Sequestration and inhibition of DAXX-mediated transcriptional repression by PML. Mol Cell Biol. 2000;20:1784–96.CrossRef
20.
Muromoto R, Sugiyama K, Takachi A, Imoto S, Sato N, Yamamoto T, Oritani K, Shimoda K, Matsuda T. Physical and functional interactions between DAXX and DNA methyltransferase 1-associated protein, DMAP1. J Immunol. 2004;172:2985–93.CrossRef
21.
Ishov AM, Vladimirova OV, Maul GG. Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternatenuclear sites of the transcription repressor DAXX and SWI/SNF protein ATRX. J Cell Sci. 2004;117:3807–20.CrossRef
22.
Li R, Pei H, Watson DK, Papas TS. EAP1/DAXX interacts with ETS1 and represses transcriptional activation of ETS1 target genes. Oncogene. 2000;19:745–53.CrossRef
23.
Lehembre F, Müller S, Pandolfi PP, Dejean A. Regulation of Pax3 transcriptional activity by SUMO-1-modifiedPML. Oncogene. 2001;20:1–9.CrossRef
24.
Lin DY, Lai MZ, Ann DK, Shih HM. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering DAXX to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem. 2003;278:15958–65.CrossRef
25.
Zhao LY, Liu J, Sidhu GS, Niu Y, Liu Y, Wang R, Liao D. Negative regulation of p53 functions by DAXX and theinvolvement of MDM2. J Biol Chem. 2004;279:50566–79.CrossRef
26.
Salomoni P. The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture. Front Oncol. 2013;3:152.CrossRef
27.
Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J, Tian J. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Tumour Biol. 2015;36:2143–53.CrossRef
28.
Jiang M, Wen F, Cao J, Li P, She J, Chu Z. Genome-wide exploration of the molecularevolution and regulatory network of mitogen-activatedprotein kinase cascades uponmultiple stresses in Brachypodium distachyon. BMC Genomics. 2015;16:228.CrossRef
29.
Knight T, Irving JA. Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting. Front Oncol. 2014;4:160.CrossRef
30.
Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 2007;104:338–44.CrossRef
31.
Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piche A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer. 2012;11:84.CrossRef
32.
Correa RJ, Peart T, Valdes YR, DiMattia GE, Shepherd TG. Modulation of AKT activity is associated with reversibledormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis. 2011;33:49–58.CrossRef
33.
Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. CCAAT/enhancer binding protein-β is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci U S A. 2002;99:207–12.CrossRef
34.
Lee HG, Minematsu H, Kim KO, Celil Aydemir AB, Shin MJ, Nizami SA, Chung KJ, Hsu AC, Jacobs CR, Lee FY. Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. Biomaterials. 2011;32:9197–206.CrossRef
35.
Mäuser W, Perwitz N, Meier B, Fasshauer M, Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol. 2007;564:37–46.CrossRef
Metadata
Title
DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway
Authors
Sheng-Bing Liu
Xue-Ping Lin
Ying Xu
Zhong-Fei Shen
Wei-Wei Pan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-018-0462-4

Other articles of this Issue 1/2018

Journal of Ovarian Research 1/2018 Go to the issue

Research

Successful fertility following optimized perfusion and cryopreservation of whole ovary and allotransplantation in a premature ovarian insufficiency rat model

Research

Diagnostic utility of CT in differentiating between ruptured ovarian corpus luteal cyst and ruptured ectopic pregnancy with hemorrhage

Research

Consanguineous familial study revealed biallelic FIGLA mutation associated with premature ovarian insufficiency

Research

Cross-linked hyaluronan gel inhibits the growth and metastasis of ovarian carcinoma

Research

DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway

Research

Is the aging human ovary still ticking?: Expression of clock-genes in luteinized granulosa cells of young and older women